EP
BDTX icon

Essential Partners’s Black Diamond Therapeutics BDTX Stock Holding History

Essential Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-43
Closed -$107 – 2681
2025
Q2 		$107 Buy
+43
New +$83 ﹤0.01% 2054

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Essential Partners's BDTX Position: Q3 2025 in Review

Essential Partners sold out of Black Diamond Therapeutics (BDTX) in Q3 2025, closing a stake of 43 shares — an estimated $107 sold.

Essential Partners first reported a position in BDTX in Q2 2025 and held it in 1 quarter. The position peaked at $107 in Q2 2025. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

  • Essential Partners reported no remaining Black Diamond Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 43 Black Diamond Therapeutics shares in Q3 2025, an estimated $107.
  • Essential Partners first reported a position in Black Diamond Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Black Diamond Therapeutics position peaked at $107 in Q2 2025.
  • 91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.